Scohia to receive an up front & additional fees of ~$67M upon achievement of regulatory, development, & sales milestones along with royalties
Kuria will be responsible for the global development, manufacturing & commercialization of SCO-116 (Nrf2 activator) for the prevention of eye & skin diseases with the guidance of JSE. Scohia obtains the global rights for SCO-116 for local delivery other than for eye, skin diseases & systemic formulation
The safety & tolerability profile of SCO-116 has been shown in preliminary 1wk. toxicology studies in rats & monkeys. SCO-116 may be used to prevent or treat a wide range of conditions with unmet medical needs, including CKD, diabetic kidney disease, NASH, liver disease, eye & skin conditions
Ref: Bussinesswire | Image: Scohia Pharma
